S&P 500   5,103.36 (-0.54%)
DOW   38,799.25 (-0.49%)
QQQ   439.36 (-1.05%)
AAPL   171.20 (-2.23%)
MSFT   409.95 (-1.20%)
META   492.85 (-1.07%)
GOOGL   132.83 (-0.39%)
AMZN   175.73 (-1.04%)
TSLA   182.76 (-2.86%)
NVDA   849.09 (-0.38%)
NIO   5.16 (-3.19%)
AMD   201.31 (-1.97%)
BABA   71.92 (-0.11%)
T   17.14 (+2.02%)
F   12.67 (-0.55%)
MU   94.95 (-0.86%)
CGC   2.96 (-1.99%)
GE   160.99 (-0.01%)
DIS   113.66 (-0.03%)
AMC   4.34 (+0.46%)
PFE   25.83 (-0.23%)
PYPL   60.30 (+0.53%)
XOM   104.89 (+0.51%)
S&P 500   5,103.36 (-0.54%)
DOW   38,799.25 (-0.49%)
QQQ   439.36 (-1.05%)
AAPL   171.20 (-2.23%)
MSFT   409.95 (-1.20%)
META   492.85 (-1.07%)
GOOGL   132.83 (-0.39%)
AMZN   175.73 (-1.04%)
TSLA   182.76 (-2.86%)
NVDA   849.09 (-0.38%)
NIO   5.16 (-3.19%)
AMD   201.31 (-1.97%)
BABA   71.92 (-0.11%)
T   17.14 (+2.02%)
F   12.67 (-0.55%)
MU   94.95 (-0.86%)
CGC   2.96 (-1.99%)
GE   160.99 (-0.01%)
DIS   113.66 (-0.03%)
AMC   4.34 (+0.46%)
PFE   25.83 (-0.23%)
PYPL   60.30 (+0.53%)
XOM   104.89 (+0.51%)
S&P 500   5,103.36 (-0.54%)
DOW   38,799.25 (-0.49%)
QQQ   439.36 (-1.05%)
AAPL   171.20 (-2.23%)
MSFT   409.95 (-1.20%)
META   492.85 (-1.07%)
GOOGL   132.83 (-0.39%)
AMZN   175.73 (-1.04%)
TSLA   182.76 (-2.86%)
NVDA   849.09 (-0.38%)
NIO   5.16 (-3.19%)
AMD   201.31 (-1.97%)
BABA   71.92 (-0.11%)
T   17.14 (+2.02%)
F   12.67 (-0.55%)
MU   94.95 (-0.86%)
CGC   2.96 (-1.99%)
GE   160.99 (-0.01%)
DIS   113.66 (-0.03%)
AMC   4.34 (+0.46%)
PFE   25.83 (-0.23%)
PYPL   60.30 (+0.53%)
XOM   104.89 (+0.51%)
S&P 500   5,103.36 (-0.54%)
DOW   38,799.25 (-0.49%)
QQQ   439.36 (-1.05%)
AAPL   171.20 (-2.23%)
MSFT   409.95 (-1.20%)
META   492.85 (-1.07%)
GOOGL   132.83 (-0.39%)
AMZN   175.73 (-1.04%)
TSLA   182.76 (-2.86%)
NVDA   849.09 (-0.38%)
NIO   5.16 (-3.19%)
AMD   201.31 (-1.97%)
BABA   71.92 (-0.11%)
T   17.14 (+2.02%)
F   12.67 (-0.55%)
MU   94.95 (-0.86%)
CGC   2.96 (-1.99%)
GE   160.99 (-0.01%)
DIS   113.66 (-0.03%)
AMC   4.34 (+0.46%)
PFE   25.83 (-0.23%)
PYPL   60.30 (+0.53%)
XOM   104.89 (+0.51%)
TSE:CPH

Cipher Pharmaceuticals (CPH) Stock Price, News & Analysis

C$7.12
-0.07 (-0.97%)
(As of 09:33 AM ET)
Today's Range
C$7.12
C$7.23
50-Day Range
C$5.45
C$7.70
52-Week Range
C$3.11
C$7.81
Volume
1,060 shs
Average Volume
27,694 shs
Market Capitalization
C$171.02 million
P/E Ratio
4.16
Dividend Yield
N/A
Price Target
C$8.00

CPH stock logo

About Cipher Pharmaceuticals Stock (TSE:CPH)

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of severe recalcitrant nodular acne; Lipofe indicated as adjunctive therapy to diet to reduce triglycerides in adult patients with severe hypertriglyceridemia; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.

CPH Stock Price History

CPH Stock News Headlines

Cipher Pharmaceuticals Inc CPH
Cipher Pharmaceuticals Inc (PHE.MU)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Cipher Pharmaceuticals Announces Change of Auditor
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Cipher Pharmaceuticals Non-GAAP EPS of -$0.12
CPH:CA Cipher Pharmaceuticals Inc.
See More Headlines
Receive CPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/10/2023
Today
3/04/2024
Next Earnings (Estimated)
3/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
C$8.00
High Stock Price Target
C$8.00
Low Stock Price Target
C$8.00
Potential Upside/Downside
+11.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
C$32.41 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$21.15 million
Cash Flow
C$2.04 per share
Book Value
C$3.06 per share

Miscellaneous

Free Float
N/A
Market Cap
C$172.70 million
Optionable
Not Optionable
Beta
0.97
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Craig J. Mull
    Interim CEO & Chairman of the Board
  • Mr. Bryan Jacobs
    Chief Financial Officer
  • Dr. Diane Gajewczyk
    Vice President of Scientific & Medical Affairs
  • Mr. Emilio Presti
    Director of Sales & Marketing














CPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Cipher Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cipher Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CPH shares.
View CPH analyst ratings
or view top-rated stocks.

What is Cipher Pharmaceuticals' stock price target for 2024?

2 Wall Street research analysts have issued 1 year target prices for Cipher Pharmaceuticals' stock. Their CPH share price targets range from C$8.00 to C$8.00. On average, they expect the company's share price to reach C$8.00 in the next year. This suggests a possible upside of 12.4% from the stock's current price.
View analysts price targets for CPH
or view top-rated stocks among Wall Street analysts.

How have CPH shares performed in 2024?

Cipher Pharmaceuticals' stock was trading at C$5.54 at the beginning of the year. Since then, CPH stock has increased by 28.5% and is now trading at C$7.12.
View the best growth stocks for 2024 here
.

When is Cipher Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our CPH earnings forecast
.

How were Cipher Pharmaceuticals' earnings last quarter?

Cipher Pharmaceuticals Inc. (TSE:CPH) posted its quarterly earnings data on Thursday, August, 10th. The company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.15 by $0.01. The firm earned $7.10 million during the quarter, compared to analysts' expectations of $7.46 million. Cipher Pharmaceuticals had a trailing twelve-month return on equity of 53.13% and a net margin of 153.23%. During the same period last year, the business posted $0.10 EPS.

What other stocks do shareholders of Cipher Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cipher Pharmaceuticals investors own include Cipher Pharmaceuticals (CPHRF), Bellatrix Exploration (BXE), Aurora Cannabis (ACB), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Catalyst Biosciences (CBIO), Crescent Point Energy (CPG) and Enbridge (ENB).

How do I buy shares of Cipher Pharmaceuticals?

Shares of CPH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:CPH) was last updated on 3/5/2024 by MarketBeat.com Staff